Meta‐Analysis: Enhanced Liver Fibrosis ( ELF ) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
Alimentary Pharmacology & Therapeutics · 2026-10 · 64 (7) · 864-889
DOI: 10.1111/apt.70846 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 24.08.2026. Verfasst von Matthew F W Gee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Siemens Healthcare Diagnostics Inc, Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Non‐invasive tests are increasingly employed to evaluate liver fibrosis associated with metabolic dysfunction–associated steatotic liver disease (MASLD). Accurate cutoffs for significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4) are critical for establishing diagnostic guidelines and qualification for MASLD‐related anti‐fibrotic therapy.
Aims
Determine optimal Enhanced Liver Fibrosis (ELF) Test MASLD cutoffs for ≥F2, ≥F3, and F4 identification and decision‐making, evaluate the appropriateness of guideline‐recommended cutoffs, and assess ELF performance.
Methods
Using four databases, we identified 34 MASLD‐focused studies conducted between 2004 and 2026 evaluating ELF cutoffs (37 cohorts): quality was assessed using Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS‐2). Multiple cutoffs were integrated using hierarchical summary receiver operating characteristic analysis. Sensitivity (Sens) and specificity (Spec) at Youden cutoffs and guideline‐recommended cutoffs were estimated using Steinhauser's hierarchical multi‐cutoff random‐effects model and R diagmeta package v0.5‐1.
Results
Youden cutoffs (AUROCs [95% CIs]) were: ≥F2: 9.37 (0.818 [0.781–0.850]); ≥F3: 9.64 (0.818 [0.782–0.850]); F4: 9.99 (0.774 [0.711–0.827]). Sens and Spec at established cutoffs were: ≥F2 (9.00) 0.86 Sens, 0.61 Spec; ≥F3 (9.80) 0.70 Sens, 0.79 Spec; F4 (11.30) 0.21 Sens, 0.96; and F4 (10.50) 0.50 Sens, 0.86 Spec. For F2 rule‐out (7.70), Sens = 0.98 and Spec = 0.14.
Conclusion
ELF < 9.00 may be useful to rule out ≥ F2 fibrosis in MASLD. ELF ≥ 9.80 and ≥ 11.30 represent balanced cutoffs for ≥F3 and F4 fibrosis, respectively. ELF ≥ 10.50 could represent an upper limit for MASLD‐related anti‐fibrotic therapeutic decision‐making. ELF at 7.70 is not a meaningful cutoff for any purpose. Trial Registration PROSPERO registration: CRD420251145859
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Siemens Healthcare Diagnostics Inc, Tarrytown, New York, USA.
- Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Epidemiology and Biostatistics, UCSF School of Medicine, University of California San Francisco, San Francisco, California, USA.
- Division of Gastroenterology, Hepatology and Nutrition, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
ORCID-Profile: Matthew F W Gee, Donald B Chalfin, Edward B De Vol, H Roma Levy, Artem T Boltyenkov, Arun J Sanyal
Zitieren
APA
Gee, M. F. W., Chalfin, D. B., De Vol, E. B., Levy, H. R., Boltyenkov, A. T., Casale, M. G., & Sanyal, A. J. (2026). Meta‐Analysis: Enhanced Liver Fibrosis ( ELF ) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics, 64(7), 864-889. https://doi.org/10.1111/apt.70846
Vancouver
Gee MFW, Chalfin DB, De Vol EB, Levy HR, Boltyenkov AT, Casale MG, et al. Meta‐Analysis: Enhanced Liver Fibrosis ( ELF ) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026;64(7):864-889. doi:10.1111/apt.70846
BibTeX
@article{Gee2026,
author = {Gee, Matthew F W and Chalfin, Donald B and De Vol, Edward B and Levy, H Roma and Boltyenkov, Artem T and Casale, Mario Gutierrez and Sanyal, Arun J},
title = {Meta‐Analysis: Enhanced Liver Fibrosis ( ELF ) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {7},
pages = {864--889},
doi = {10.1111/apt.70846}
}
EUVIMED